Table 2.
Univariate analysis of prognostic factors affecting RFI, OS1, PFS and OS2
| Factors | Median RFI (months) | Pvalue* | Median OS1(months) | Pvalue* | Median PFS (months) | Pvalue* | Median OS2(months) | Pvalue* |
|---|---|---|---|---|---|---|---|---|
| Age |
|
|
|
|
|
|
|
|
| ≤ 50 |
NA† |
|
NA† |
|
10.0 |
0.868 |
36.5 |
0.966 |
| > 50 |
|
|
10.9 |
|
NR |
|
||
| Menstruation status |
|
|
|
|
|
|
|
|
| Pre-menopausal |
NA† |
|
NA† |
|
9.5 |
0.985 |
36.5 |
0.565 |
| Post-menopausal |
|
|
11.3 |
|
NR |
|
||
| Histology |
|
|
|
|
|
|
|
|
| IDC |
31.5 |
0.550 |
130.8 |
0.454 |
10.4 |
0.513 |
36.5 |
0.560 |
| ILC |
36.4 |
|
NR |
|
4.4 |
|
NR |
|
| Others |
39.1 |
|
72.8 |
|
17.2 |
|
32.6 |
|
| Luminal subtype |
|
|
|
|
|
|
|
|
| Luminal A |
41.2 |
<0.001 |
222.1 |
0.011 |
11.6 |
0.550 |
36.5 |
0.233 |
| Luminal B |
24.2 |
|
71.7 |
|
9.4 |
|
32.6 |
|
| Adjuvant/neoadjuvant therapy |
|
|
|
|
|
|
|
|
| Only CT (± RT) |
17.7 |
0.138 |
NR |
0.927 |
5.1 |
0.463 |
NR |
0.639 |
| Only HT (± RT) |
17.2 |
|
NR |
|
23.2 |
|
NR |
|
| CT + HT (± RT) |
36.1 |
|
NR |
|
11.3 |
|
NR |
|
| Therapy with TT |
28.9 |
|
NR |
|
8.4 |
|
NR |
|
| No |
28.9 |
|
NR |
|
13.7 |
|
NR |
|
| Relapse-free interval |
|
|
|
|
|
|
|
|
| ≤ 2 years |
NA |
|
NA |
|
8.2 |
0.003 |
22.8 |
0.017 |
| > 2 years |
|
|
12.9 |
|
NR |
|
||
| No. of metastatic sites |
|
|
|
|
|
|
|
|
| 1 |
NA |
|
NA |
|
13.0 |
0.002 |
NR |
0.032 |
| 2 |
|
|
16.5 |
|
32.6 |
|
||
| ≥ 3 |
|
|
8.4 |
|
25.1 |
|
||
| Visceral metastasis |
|
|
|
|
|
|
|
|
| Yes |
NA |
|
NA |
|
9.0 |
0.035 |
36.5 |
0.393 |
| No |
|
|
13.3 |
|
NR |
|
||
| First-line therapy after PET/CT |
|
|
|
|
|
|
||
| HT |
NA |
|
NA |
|
21.0 |
0.037 |
NR |
0.019 |
| CT (± TT) |
|
|
9.5 |
|
32.6 |
|
||
| Baseline SUVmax |
|
|
|
|
|
|
|
|
| ≤ 5.60 (Lowest tertile) |
NA | |
NA | |
19.2 |
0.002 |
NR |
0.009 |
| 5.60 ~ 8.70 (Intermediate tertile) |
|
|
10.4 |
|
35.3 |
|
||
| > 8.70 (Highest tertile) | 8.2 | 22.6 | ||||||
RFI: relapse-free interval; OS: overall survival; PFS: progression-free survival; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; CT: chemotherapy; RT: radiotherapy; HT: hormonal therapy; TT: target therapy; No.: number; SUVmax: the maximum standardized uptake value; NA: not applicable; NR: not reached.
* Log-rank test.
† The data of age and menstruation status were collected after diagnosis of relapse and informed consent obtained. These data were different from those at diagnosis of primary breast cancer.